letermovir (Prevymis)
Jump to navigation
Jump to search
Indications
Dosage
- 480 mg PO/IV QD, 240 mg QD if also taking cyclosporine
- initiate between day 0 & day 28 posttransplantation (before or after engraftment) & continue through day 100
Tabs: 240 mg, 480 mg
Injection: 20 mg/mL, vials 12 mL, 24 mL
Adverse effects
Drug interactions
Mechanism of action
- inhibits the CMV DNA terminase complex (pUL51, pUL56, & pUL89), thus interferes with viral DNA processing & virion maturation
More general terms
References
- ↑ RxNorm
- ↑ Wikipedia: Letermovir https://en.wikipedia.org/wiki/Letermovir
- ↑ Lowes R Letermovir (Prevymis) Okayed for Stem Cell Transplant Infection. Medscape. Nov 9, 2017 https://www.medscape.com/viewarticle/888295
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Marty FM, Ljungman P, Chemaly RF Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic- Cell Transplantation. N Engl J Med. Dec 6, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29211658 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1706640